This site became the new on June 19th. Learn more.
Show more Menu IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu IMPORTANT: Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu
Give us feedback

Aldosterone in Diabetic Nephropathy (ALDODN)

The recruitment status of this study is unknown. The completion date has passed and the status has not been verified in more than two years.
Verified March 2009 by Universidad Los Andes, Chile.
Recruitment status was:  Recruiting
Information provided by:
Universidad Los Andes, Chile Identifier:
First received: March 25, 2009
Last updated: NA
Last verified: March 2009
History: No changes posted
The purpose of this study is to determine whether spironolactone are effective in the reduction of albuminuria and diastolic disfunction of subjects with diabetic nephropathy.

Condition Intervention Phase
Diabetic Nephropathy Drug: Spironolactone Drug: Placebo Phase 4

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Triple (Participant, Care Provider, Investigator)
Primary Purpose: Treatment
Official Title: Effect of Aldosterone Antagonism in the Reduction of Albuminuria and Diastolic Disfunction of Patients With Diabetic Nephropathy.

Resource links provided by NLM:

Further study details as provided by Universidad Los Andes, Chile:

Primary Outcome Measures:
  • Reduction of albuminuria [ Time Frame: 9 months ]

Secondary Outcome Measures:
  • Reduction of diastolic disfunction [ Time Frame: 9 months ]

Estimated Enrollment: 160
Study Start Date: March 2009
Estimated Study Completion Date: March 2010
Estimated Primary Completion Date: December 2009 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: 1 Drug: Spironolactone
25 mg per day for 9 months
Placebo Comparator: 2 Drug: Placebo
Placebo 1 tablet per day for nine months


Ages Eligible for Study:   30 Years to 70 Years   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Diabetic subjects with maximum ten years after diagnostic
  • Diabetic nephropathy with albuminuria
  • Normal renal function
  • Diastolic disfunction
  • Taking a IECA or ARA drug family previously

Exclusion Criteria:

  • Diabetics subjects with macroangiopathy
  • Acute coronary syndrome in the three months before
  • Hyperkalemia > 5.5 mEq/L
  • Pregnancy
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00870402

Contact: Francisco G Espinoza, MD 56 - 2 -91380529 ext 000

University of Los Andes Recruiting
Santiago, Chile, 762000
Contact: Helia M Morales, MD    56 - 2 - 93381451 ext 000   
Principal Investigator: Francisco G Espinoza, MD         
Sponsors and Collaborators
Universidad Los Andes, Chile
  More Information

Responsible Party: Francisco Espinoza Villegas, Departament of Internal Medicine, University of los Andes Identifier: NCT00870402     History of Changes
Other Study ID Numbers: SA08I20032
Study First Received: March 25, 2009
Last Updated: March 25, 2009

Keywords provided by Universidad Los Andes, Chile:
diastolic disfunction

Additional relevant MeSH terms:
Kidney Diseases
Diabetic Nephropathies
Urologic Diseases
Diabetes Complications
Diabetes Mellitus
Endocrine System Diseases
Mineralocorticoid Receptor Antagonists
Hormone Antagonists
Hormones, Hormone Substitutes, and Hormone Antagonists
Physiological Effects of Drugs
Diuretics, Potassium Sparing
Natriuretic Agents processed this record on September 21, 2017